title: Treatment of ANCA-associated vasculitides (AAV).
abstract: Treatment of AAV follows the principle of a combined remission induction and maintenance strategy and is adapted in a stage and activity-adapted fashion. So far the combination therapy of glucocorticoids and conventional immunosuppressive drugs has mainly been used to control disease. This approach has led to a significant improvement in outcome in spite of persistently high early mortality rates of nearly 11% within the first year. Besides conventional treatment, biologics have emerged as a new treatment option. The paper summarizes the current evidence for the use of conventional therapy and biologics in AAV.
authors.affiliation: Vasculitis Center, University Hospital Schleswig-Holstein, Campus Lübeck and Klinikum Bad Bramstedt, Germany. j.holle@klinikumbb.de
authors.forename: Julia U
authors.initials: JU
authors.lastname: Holle
authors.forename: Wolfgang L
authors.initials: WL
authors.lastname: Gross
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy*; D015267:Churg-Strauss Syndrome / Q000188:drug therapy; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D055953:Microscopic Polyangiitis / Q000188:drug therapy; D012008:Recurrence; D012074:Remission Induction
chemical_list: D007166:Immunosuppressive Agents